NEOPROBE Share Price OTC Bulletin Board
Equities
NEOP
US6405181065
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | 532K 44.34M | Sales 2022 | 65.65K 5.48M | Capitalization | 6.78M 565M |
---|---|---|---|---|---|
Net income 2021 | -11M -918M | Net income 2022 | -15M -1.25B | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 3.48M 290M | Net Debt 2022 | 440K 36.69M | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 28/23/28 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Richard McFerron
LAW | General Counsel | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 30/22/30 |
John Scott
BRD | Director/Board Member | 69 | 08/21/08 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 01/23/01 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- NAVB Stock
- NEOP Stock